• LAST PRICE
    1.9750
  • TODAY'S CHANGE (%)
    Trending Up0.0650 (3.4031%)
  • Bid / Lots
    1.9700/ 11
  • Ask / Lots
    1.9800/ 5
  • Open / Previous Close
    1.9600 / 1.9100
  • Day Range
    Low 1.9300
    High 2.0300
  • 52 Week Range
    Low 0.5300
    High 3.0301
  • Volume
    100,964
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 1.91
TimeVolumeCGEN
09:32 ET173901.93
09:34 ET39541.95
09:36 ET113001.965
09:38 ET15501.97
09:39 ET107012.005
09:43 ET25592.01
09:45 ET103052
09:48 ET10141.98
09:50 ET11001.95
09:52 ET30001.98
09:54 ET7001.98
09:56 ET7031.985
09:57 ET6001.98
09:59 ET1001.975
10:01 ET8741.965
10:03 ET14001.965
10:06 ET52111.97
10:08 ET2001.98
10:10 ET28621.98
10:14 ET6001.9899
10:19 ET1021.995
10:21 ET8001.995
10:28 ET2001.995
10:30 ET16001.99
10:32 ET6931.99
10:33 ET50921.9883
10:35 ET17191.975
10:37 ET41231.97
10:42 ET1001.975
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCGEN
Compugen Ltd
171.0M
-9.1x
---
United StatesFHTX
Foghorn Therapeutics Inc.
221.8M
-2.2x
---
United StatesCLLS
Cellectis SA
184.6M
-1.4x
---
United StatesCAPR
Capricor Therapeutics Inc
158.8M
-5.7x
---
United StatesGNFT
Genfit SA
171.2M
-5.6x
---
United StatesMDWD
Mediwound Ltd
167.0M
-23.0x
---
As of 2024-04-25

Company Information

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Contact Information

Headquarters
Azrieli Center, 26 Harokmim St. Bldg DHOLON, Israel 5885849
Phone
---
Fax
---

Executives

Non-Executive Independent Chairman of the Board
Paul Sekhri
President, Chief Executive Officer, Director
Anat Cohen-Dayag
Chief Financial Officer, Chief Operating Officer
Ari Krashin
Senior Vice President, Corporate and Business Development
Oliver Froescheis
Senior Vice President, Technology Innovation
Zurit Levine

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$171.0M
Revenue (TTM)
$33.5M
Shares Outstanding
89.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.73
EPS
$-0.22
Book Value
$0.73
P/E Ratio
-9.1x
Price/Sales (TTM)
5.1
Price/Cash Flow (TTM)
---
Operating Margin
-38.83%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.